Remove 2016 Remove Leads Remove Physicians Remove Safety
article thumbnail

Comparison of Humira biosimilars in the US and Europe

Pharmaceutical Technology

However, it has taken over six years for Amjevita to launch, after first being FDA-approved in 2016. Many other biosimilars have also been FDA-approved since 2016. Further, there remains scepticism on the efficacy and safety of biosimilars. Sometimes the settlement of a patent dispute involves agreeing to defer entry.

article thumbnail

Redesigning Provider Incentives to Influence Practice Patterns and Performance

Clarify Health

Placing clinicians at financial risk for controlling health costs and improving quality without equipping them with the tools to do so leads to frustration and disillusionment. Physicians dislike being outliers and adjust their practice patterns to conform when provided with a relative social ranking. million on orthopedic MS-DRGs.[1]

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How Pharmacogenomics may finally realise its promise

pharmaphorum

In 2016, the estimated annual cost of drug-related morbidity and mortality resulting from non-optimised medication therapy was $528.4 The best way to do that is to target specific sub-populations, which will serve as a natural lead into personalised medicine becoming more mainstream. billion in the United States alone.

article thumbnail

The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

PharmaKinnex

The pharmaceutical industry of 2022 is very different from the space that we all knew in 2012, 2016, or even 2020. More convenience and safety? PharmaKinnex knows that identifying, qualifying, and then directing leads toward a successful sale is extremely difficult in today’s environment. August 23, 2022. What’s not to love?

Pharma 52
article thumbnail

In-Office Pediatric Ear Tube Procedures: Interview with Preceptis Medical’s Greg Mielke

Medgadget

Otitis media generates about 25 million annual office visits to general physicians and pediatricians, with the highest prevalence occurring in children 3-6 months. Fluid buildup and middle ear infections can also lead to hearing loss that can result in delayed speech development and poor school performance.

FDA 95
article thumbnail

The FDA now recommends that clinical trial sponsors submit a Race and Ethnicity Diversity Plan

Clarify Health

The plan should define enrollment goals for underrepresented racial and ethnic participants, indicate the potential safety or efficacy differences among these participants, and outline the plan to collect data and explore differences between subgroups.

FDA 52
article thumbnail

The FDA now recommends that clinical trial sponsors submit a Race and Ethnicity Diversity Plan

Clarify Health

The plan should define enrollment goals for underrepresented racial and ethnic participants, indicate the potential safety or efficacy differences among these participants, and outline the plan to collect data and explore differences between subgroups.

FDA 52